Cargando…
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
Ribociclib plus an aromatase inhibitor and ovarian function suppression is the preferred first-line option for pre-/perimenopausal women with hormone receptor-positive/human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer. We opened an italian managed access program...
Autores principales: | Staropoli, Nicoletta, Geuna, Elena, Rinaldi, Gaetana, Bisagni, Giancarlo, Scotti, Vieri, Faggioni, Giovanni, Vannini, Laura, Arcara, Carlo, Moretti, Gabriella, Gunnellini, Marco, Coltelli, Luigi, Verderame, Francesco, Livi, Lorenzo, Sanna, Giuseppina, Grasso, Donatella, Abbinante, Giulia, Ragni, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498176/ https://www.ncbi.nlm.nih.gov/pubmed/36135090 http://dx.doi.org/10.3390/curroncol29090521 |
Ejemplares similares
-
Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
por: Jonat, W.
Publicado: (1998) -
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
por: Lu, Yen-Shen, et al.
Publicado: (2021) -
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
por: Jeong, Eunae, et al.
Publicado: (2021) -
Cost-effectiveness of ribociclib for premenopausal or perimenopausal
women with HR+/HER2− advanced breast cancer: a Brazilian public health care
system perspective
por: Rosa, Daniela Dornelles, et al.
Publicado: (2022) -
Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)